SciCombinator

Discover the most talked about and latest scientific content & concepts.

M Kudrimoti, A Curtis, S Azawi, F Worden, S Katz, D Adkins, M Bonomi, Z Scott, J Elder, ST Sonis, R Straube and O Donini
Abstract
Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
Tweets*
1
Facebook likes*
0
Reddit*
0
News coverage*
65
Blogs*
0
SC clicks
0
Concepts
The Canon of Medicine, Epidemiology, Head and neck anatomy, Chemotherapy, Oncology, Innate immune system, Clinical trial, Immune system
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com